0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Multicell Technologies
Its shares trade under the ticker MCET. It has been listed since 16 June 1994. In the fiscal year to 30 November 2014, it reported revenue of $49,300 and a net loss of $380,100. At that date it held total assets of $126,200 and shareholders' equity of −$144,300.
MultiCell Technologies, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Woonsocket, Rhode Island. The firm and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The firm's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jun 1994
- Employees
- 2
- Website
- multicelltech.com ↗
Leadership
Pay as last reported
- Mr. W. Gerald NewminChairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, since 1995$185,720
- Dr. Stephen ChangDirector, since 2004$28,385
- Mr. Grant MillerDirector
- Mr. Thomas PageIndependent Director
- Mr. Edward SigmondIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Multicell Technologies Inc is known for its advanced research and development capabilities, which allow the company to innovate and develop cutting-edge technologies in the field of cell biology.
- The company has a strong intellectual property portfolio, including patents and trademarks, giving it a competitive advantage and providing barriers to entry for potential competitors.
- Multicell Technologies Inc has established strategic partnerships with key industry players, enabling access to additional resources and expertise in various areas of the business.
Weaknesses
- The company relies heavily on external funding to support its research and development activities, which exposes it to risks associated with changes in funding availability or investor sentiment.
- Multicell Technologies Inc faces challenges in scaling up its production processes to meet increasing market demand, which may result in delays or production inefficiencies.
- The company's current product portfolio is limited and highly focused, making it vulnerable to shifts in market trends or technological advancements that could render their products obsolete.
Opportunities
- The growing demand for cell-based therapies and regenerative medicine presents significant opportunities for Multicell Technologies Inc to expand its product offerings and enter new markets.
- Advancements in technology and increasing public awareness of the potential of cell-based treatments provide a favorable market environment for the company to gain a competitive advantage.
- Multicell Technologies Inc can leverage its research capabilities to develop strategic partnerships with pharmaceutical companies, opening up opportunities for collaboration and co-developing products for specific applications.
Threats
- The regulatory landscape for cell-based therapies is complex and subject to change, posing potential challenges and delays in obtaining necessary approvals for commercialization.
- Competition in the cell biology industry is intensifying, with the entry of new players and established companies investing heavily in research and development. This competitive pressure may erode Multicell Technologies Inc's market share.
- Economic downturns or financial instability in the healthcare sector could impact customer spending and reduce demand for the company's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.